News Feed Item

Delivra Reports Record Q3 Revenues and Licensing Agreement for the Transdermal Delivery of Medical Cannabis During the Quarter

TORONTO, ON--(Marketwired - November 30, 2016) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") reported its financial results for the three and nine month periods ended September 30, 2016. All figures are reported in CDN dollars ($), unless otherwise indicated. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Q3 2016 Highlights:

  • Solidified the Company's position as having the #1 Selling Natural Pain Cream in Canada and the #1 Selling Nerve Pain Cream in Canada (adapted from Nielson data, April 2016);
  • Completed a licensing agreement with Canopy Growth Corporation (TSX: CGC) for the transdermal delivery of medical cannabis;
  • Q3-2016 generated revenues of $630,265, a 42% increase over Q3-2015. Pain and nerve sales are seasonal and historically the slowest during the third quarter of each year;
  • Filed four permanent patents during the quarter, bringing the total number of patents pending to six and the total number of permanent patent filings to four;
  • Secured an additional $495,000 of government funding relating to the U.S. market entry in the form of unsecured, interest-free loans;
  • Received proceeds on interest-free government loans in the amount of $280,397, and after quarter end, an additional $653,518. Proceeds received were used for scientific research on certain transdermal products and U.S. market entry expenditures;
  • Raised $2,020,900 through the issuance of convertible debentures on a non-brokered private placement;
  • R&D development of the transdermal delivery potential of the very popular pain management drug, celecoxib;
  • Starting in June and throughout Q3-2016, investment made in building brand awareness in the U.S.; and
  • Subsequent to quarter end, the Company announced its successful pre-clinical work with the natural ingredient berberine for the prevention and treatment of cardiovascular disease related to high cholesterol and triglyceride levels.

"Our strategy of improving the safety and efficacy of existing drugs using Delivra's proprietary transdermal delivery technology platform continues to drive a portfolio of robust pharmaceutical and natural products in our pipeline. During the quarter, we successfully grew our LivRelief suite of products in Canada, while leveraging the value of our delivery system platform, including diabetes and innovative cannabis-based products. The completion of a licensing agreement with Canopy Growth Corporation, our second licensing agreement for the transdermal delivery of medical cannabis, addresses the growing demand for topical cannabis as a therapeutic option for a range of conditions. Through this collaboration, Delivra will offer consumers a unique product suite. We are excited at the opportunity of licensing these natural and Rx products globally," said Dr. Joseph Gabriele, CEO of Delivra Corp.

Results of Operations


Revenue for Q3-2016 was $630,265, a 42% increase compared to Q3-2015 of $444,866. Revenues for the first nine months of 2016 were $2,734,768, an increase of 32% compared to the same period in 2015 of $2,071,270. The main drivers of this growth for the first nine months of 2016 were:

  1. 34% increase in adjusted unit sales over the comparative period of the Company's pain products in Canada, including repeat purchases and new customer acquisitions resulting from the Company's on-going marketing and advertising efforts, and
  2. 54% increase in unit sales over the comparative period of the Company's Nerve Pain product in Canada.

This increase in nerve product sales is a result of a planned reallocation of marketing and advertising expenditures beginning in Q2-2016. The nerve product advertising represented an investment by the Company in the latent growth potential of the product, which the Company believes is underrepresented in the overall revenue mix by comparison to the flagship Pain product. While this may result in lower revenue in the short-term, versus the same advertising spending allocation to Pain product, it strengthens the brand, solidifies the leadership position of Nerve, diversifies the customer base, and provides a broader platform for continued forward growth.

Gross Profit

Gross Profit for Q3-2016 was $406,919, a 45% increase compared to Q3-2015 of $280,032. This is a result of increased revenues and efficiencies in the production process during the year (65% in Q3-2016 versus 63% in Q3-2015). Gross Profit for the first nine months of 2016 was up 36% against the comparable prior period, at $1,864,363 versus $1,374,785 in the first nine months of 2015. Gross margin was 68% in the first nine months of 2016 versus 66% in the first nine months of 2015.

Operating Expenses

Operating expenses for Q3-2016 were $2,334,223, up from $1,026,681 in Q3-2015. Operating expenses for the first nine months of 2016 were $5,596,783, versus $2,803,483 in the first nine months of 2015. The increase was mainly a result of higher marketing and selling costs associated with successful growth and brand building investments in Canada and initial US test marketing costs. In Canada, in the first nine months of 2016, the Company spent approximately $200,000 more in television advertising, which generated an additional $489,578 in gross margins, compared to the prior period. Sales and marketing salaries increased approximately $110,000 during the year, as a result of diversification and growth initiatives into professional channels (eg. medical and clinical). Lastly, the Company spent approximately $2,125,000 on aggressive US brand building initiatives during the nine-month period. Although the Company will continue with these efforts, it will be on a less aggressive basis in Q4 2016 and 2017, as the Company continues to refine and develop strategies for the US market based on the knowledge gained from these efforts.

Net Loss

The net loss and comprehensive loss for Q3-2016 was $2,246,347 or $0.06 per share versus $772,541 or $0.02 per share for Q3-2015. The net loss and comprehensive loss for the first nine months of 2016 was $4,241,331 or $0.11 per share versus $1,494,435 in the first nine months of 2015 or 0.05. The increased loss occurred from the results of operations discussed above, primarily the investments made in core growth, US expansion, share-based compensation and public company G&A costs. In addition, the loss for the three and nine months includes $266,596 relating to the accretion expense on convertible debentures and fair value change in derivatives related to the convertible debentures.


Delivra Corp. ("Delivra" or the "Company") is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport™ brand for sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the transdermal delivery of repurposing Rx molecules to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com for Canada and www.livrelief.com/us for the United States.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation's filings with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

Investor Relations:

Nicole Marchand
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...